Research Topics
| Kathleen B SchwarzSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis CKathleen B Schwarz
Department of Pediatrics, Division of Gastroenterology and Nutrition, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Gastroenterology 140:450-458.e1. 2011..We conducted a randomized controlled trial of PEG and ribavirin, compared with PEG and placebo, in children 5 to 17 years old with chronic hepatitis C...
Hepatitis B vaccination rate of homeless children in BaltimoreK Schwarz
Department of Pediatrics, Johns Hopkins University School of Medicine, and Baltimore City Health Department, Baltimore, Maryland 21287, USA
J Pediatr Gastroenterol Nutr 41:225-9. 2005..To investigate the hepatitis B vaccination rate in homeless children 2 to 18 years old living in Baltimore City...- Plasma markers of platelet activation in cystic fibrosis liver and lung diseaseKathleen B Schwarz
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Pediatr Gastroenterol Nutr 37:187-91. 2003.... - Positive impact of a shelter-based hepatitis B vaccine program in homeless Baltimore children and adolescentsKathleen Schwarz
Johns Hopkins University School of Medicine, 600 N Wolfe Street Brady 320, Baltimore, MD 21287, USA
J Urban Health 85:228-38. 2008..A brief exposure to a culturally appropriate HBV video improves HBV knowledge and may improve return rates for vaccine... - Pediatric issues in new therapies for hepatitis B and CKathleen B Schwarz
Department of Pediatric Gastroenterology and Nutrition, Johns Hopkins Children s Center, 600 North Wolfe Street, Brady 320, Baltimore, MD 21287, USA
Curr Gastroenterol Rep 5:233-9. 2003..Given the lack of data regarding treatment of HCV in children, it is generally agreed among pediatric hepatologists that the optimal treatment is within the context of randomized, controlled trials... 
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infectionKathleen B Schwarz
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Pediatr Gastroenterol Nutr 46:423-8. 2008..To develop a protocol for safe performance of percutaneous liver biopsies in children with deficiency of factor VIII (n = 12) or IX (n = 2) and chronic hepatitis C virus infection...- Seroprevalence of HCV infection in homeless Baltimore familiesKathleen B Schwarz
Department of Pediatrics, Johns Hopkins Medical Institutions, Johns Hopkins Children s Center, Baltimore, MD 21287, USA
J Health Care Poor Underserved 19:580-7. 2008..Conclusion. The homeless families were very receptive to our HCV seroprevalence study and are likely also to be receptive to shelter-based HCV prevention programs for young children and adolescents as well as for adults... - Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis CKathleen B Schwarz
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
J Pediatr Gastroenterol Nutr 43:499-505. 2006..In conclusion, our findings provide a basis for larger studies evaluating the efficacy and safety of pegINF-alpha2a as monotherapy as well as in combination with ribavirin in pediatric patients with chronic hepatitis C... - Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infectionKaren F Murray
Division of Gastroenterology and Nutrition, Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
Clin Trials 4:661-73. 2007..Establishment of the research team, protocol, administrative infrastructure, and ancillary contributors for the pediatric trial took years of planning... - Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis BBarbara A Haber
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Pediatrics 124:e1007-13. 2009.... - Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis CAdriana A Byrnes
Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
J Leukoc Biol 81:825-34. 2007..No differences in pretreatment IL-12 productive capacity were seen between patient groups. However, therapy with IFN-alpha led to suppression of inducible IL-12 production throughout the course of therapy in both groups of patients... - Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferonMichael R Narkewicz
Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Colorado Denver School of Medicine and The Children s Hospital, Aurora, CO 80045, USA
J Pediatr Gastroenterol Nutr 51:183-6. 2010..Our purpose is to describe the ophthalmologic complications of pegylated interferon-alpha2a with either placebo or ribavirin in children with chronic HCV (the PEDS-C trial)... - An analysis of published trials of interferon monotherapy in children with chronic hepatitis CKaren R Jacobson
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Pediatr Gastroenterol Nutr 34:52-8. 2002.... - High prevalence of overweight and obesity in homeless Baltimore children and their caregivers: a pilot studyKathleen B Schwarz
Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
MedGenMed 9:48. 2007..Because obesity is currently a major public health issue in the United States, it is possible that obesity has supplanted nutritional deficiencies as the "new malnutrition" of the homeless... - Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research ConsortiumPatricia A DeRusso
Johns Hopkins School of Medicine and The Johns Hopkins Children s Center, Baltimore, Maryland, USA
Hepatology 46:1632-8. 2007..The combination of intermediate bilirubin concentrations and poor mean weight z-scores 3 months after HPE was also associated with poor clinical outcome... - Primary liver carcinoma arising in people younger than 30 yearsWalter M Klein
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Am J Clin Pathol 124:512-8. 2005..HCCs are the most common primary liver carcinoma in children and young adults followed by FLCs. They are morphologically similar to adult HCC, but more likely to be CK7(+)... - Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplantW Leung
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Transplantation 67:1487-9. 1999..B cell lymphoproliferative disorders (LPD) and liver rejection are major lethal complications after hepatic transplantation. Reduction in immunosuppression is the treatment for the former, but is a risk factor for the latter... - New-onset autoimmune hepatitis in young patients with preexisting liver diseaseAglaia Zellos
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States
Dig Liver Dis 42:657-60. 2010..The occurrence of AIH in these patients may be due to a complex interaction between the underlying liver disease, chronic medication use and genetic predisposition resulting in altered immunoregulatory mechanisms... - Outcome after percutaneous endoscopic gastrostomy in children and young adultsJohn E Fortunato
Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Pediatr Gastroenterol Nutr 50:390-3. 2010..We hypothesized that definable preoperative clinical factors predict the need for further intervention to provide enteral access after PEG. Our aim was to identify factors associated with PEG outcome... - Viral hepatitisKathleen B Schwarz
The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Pediatr Gastroenterol Nutr 35:S29-32. 2002 - Epidemiology of primary hepatic malignancies in U.S. childrenAnil Darbari
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Hepatology 38:560-6. 2003..Hepatocellular carcinoma has worse survival rates than hepatoblastoma, and its incidence has not increased. Better maintenance of databases may provide information about associated factors behind this unexpected occurrence... - Alagille syndrome and liver transplantationBinita M Kamath
Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
J Pediatr Gastroenterol Nutr 50:11-5. 2010.... - Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipientsEstella M Alonso
Department of Pediatrics, Children s Memorial Hospital, 2300 Children s Plaza, Box 65, Chicago, IL 60614, USA
J Pediatr 156:270-6.e1. 2010..To investigate the distribution of health-related quality of life in pediatric liver transplant recipients compared with a normative population... - Immunopathogenesis of chronic hepatitis C virus infectionDing-You Li
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA
J Pediatr Gastroenterol Nutr 35:260-7. 2002 - Fractures in biliary atresia misinterpreted as child abusePatricia A DeRusso
Department of Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
Pediatrics 112:185-8. 2003..Pediatricians should be aware of an increased incidence of fractures and overall prevalence of bone disease in this population... - Autoimmune hepatitisDing-You Li
Department of Pediatrics, Children's Mercy Hospital and University of Missouri, Kansas City School of Medicine, 64108, USA
Adolesc Med Clin 15:131-43, x. 2004.... - Clinical trial of lamivudine in children with chronic hepatitis BMaureen M Jonas
of Gastroenterology, Children's Hospital, Boston, MA 02115, USA
N Engl J Med 346:1706-13. 2002..CONCLUSIONS: In children with chronic hepatitis B, 52 weeks of treatment with lamivudine was associated with a significantly higher rate of virologic response than was placebo... - Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C TrialZachary D Goodman
Armed Forces Institute of Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
Hepatology 47:836-43. 2008.... - Treatment options for chronic hepatitis B and C infection in childrenWinita Hardikar
Royal Children s Hospital, Department of Gastroenterology and Nutrition, Melbourne, Australia
Expert Rev Anti Infect Ther 4:583-91. 2006..By contrast, treatment indication for CHC in children remains controversial. If used, combination therapy with pegylated interferon and ribavirin is likely to produce the highest rates of sustained viral response... - Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis BEtienne M Sokal
Departement de Pediatrie, Cliniques Universitaires St Luc, Universite Catholique de Louvain, Brussels, Belgium
Hepatology 43:225-32. 2006..However, the incidence of YMMD mutations increased over time and resulted in lower response rates. VR was maintained in most patients who had initially responded to lamivudine in the first 12 months...
Research Grants
- VIRAL HEPATITIS IN CHILDREN OF INJECTION DRUG USERSKathleen Schwarz; Fiscal Year: 2003....
- Novel Antigens & T & B Cell Responses in Biliary AtresiaKathleen Schwarz; Fiscal Year: 2007..Novel BA-specific peptides, monospecific antibodies, and BA-dimers could be used for early diagnosis, identification of cellular targets and intrahepatic T cells. ..
- Pegylated Interferon +/- Ribavirin for Children with HCVKathleen Schwarz; Fiscal Year: 2007..Other endpoints include biochemical and clinical safety assessments. This trial would thus provide critically needed data to guide safe and effective treatment of CHC, a major cause of liver disease in children ..